Lenalidomide-d5

Modify Date: 2024-01-10 12:16:59

Lenalidomide-d5 structure	Common Name	Lenalidomide-d5
	CAS Number	1227162-34-6	Molecular Weight	264.29
	Density	1.5±0.1 g/cm3	Boiling Point	614.0±55.0 °C at 760 mmHg
	Molecular Formula	C₁₃H₈D₅N₃O₃	Melting Point	N/A
	MSDS	N/A	Flash Point	325.1±31.5 °C

Use of Lenalidomide-d5

Lenalidomide-d5 is deuterium labeled Lenalidomide. Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells[1][2].

Name	3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)-2,6-(3,4,4,5,5-2H5)piperidinedione
Synonym	More Synonyms

Description	Lenalidomide-d5 is deuterium labeled Lenalidomide. Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells[1][2].
Related Catalog	Signaling Pathways >> Apoptosis >> Apoptosis Research Areas >> Cancer Research Areas >> Inflammation/Immunology Signaling Pathways >> PROTAC >> Ligand for E3 Ligase
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Krönke J, et al. Lenalidomide induces degradation of IKZF1 and IKZF3. Oncoimmunology. 2014 Jul 3;3(7):e941742. [3]. Kotla V, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009 Aug 12;2:36. [4]. Lopez-Girona A, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012 Nov;26(11):2326-35. [5]. Rozewski DM, et al. Pharmacokinetics and tissue disposition of lenalidomide in mice. AAPS J. 2012 Dec;14(4):872-82. [6]. Minzel W, et al. Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models. Cell. 2018 Sep 20;175(1):171-185.e25. [7]. Nagashima, Takeyuki, et al. PHARMACEUTICAL COMPOSITION COMPRISING BICYCLIC NITROGEN-CONTAINING AROMATIC HETEROCYCLIC AMIDE COMPOUND AS ACTIVE INGREDIENT. Patent. 20170360780A1. [8]. Omran A, et al. Effects of MRP8, LPS, and lenalidomide on the expressions of TNF-α , brain-enriched, and inflammation-related microRNAs in the primary astrocyte culture. ScientificWorldJournal. 2013 Sep 21;2013:208309.

Density	1.5±0.1 g/cm3
Boiling Point	614.0±55.0 °C at 760 mmHg
Molecular Formula	C₁₃H₈D₅N₃O₃
Molecular Weight	264.29
Flash Point	325.1±31.5 °C
Exact Mass	264.127075
LogP	-1.39
Vapour Pressure	0.0±1.8 mmHg at 25°C
Index of Refraction	1.672

2,6-Piperidinedione-3,3,4,4,5-d5, 5-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-

MFCD15071270

3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)-2,6-(3,4,4,5,5-2H5)piperidinedione

Lenalidomide-d5

Use of Lenalidomide-d5

Names

Lenalidomide-d5 Biological Activity

Chemical & Physical Properties

Synonyms